chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Dry skin; itchy (rash); Rash on back; This spontaneous case was reported by a consumer and describes the occurrence of DRY SKIN (Dry skin), RASH PRURITIC (itchy (rash)) and RASH (Rash on back) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No adverse event history).   On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced DRY SKIN (Dry skin), RASH PRURITIC (itchy (rash)) and RASH (Rash on back). At the time of the report, DRY SKIN (Dry skin), RASH PRURITIC (itchy (rash)) and RASH (Rash on back) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment information was not provided.  Concomitant medication was not provided.   Reporter did not allow further contact
The fist day I started feeling dizzy and stomach didn't feel good. On the second day I started having problems with my vision in my left eye, I went blind for 20minutes. When I did get my Vision back I got and slight headache.  About 3am in the morning, I woke up like someone hit me in the head with a hammer. After that every second or third day the pain would come back and it would be worse, it brought tears to my eyes. I started taking Tylenol but then it stopped working.  it kept kept getting worse and I went to see my Dr. and she put me on some medication, but they did work and she sent me to a Neurologist and he put two medications. They seem to be working, I'm not having them as much. I'm calling tomorrow to see when my appointment is scheduled.
Information was received from a certified medical assistant concerning multiple unspecified patients, who on unknown dates, were vaccinated with RECOMBIVAX HB (0.5 ml, once, intramuscularly) that were exposed to temperatures outside of recommended condition. No adverse events were reported. No further information was provided. This is one of four reports from the same reporter. Additional information has been requested.
Patient said she is experiencing severe pain in her upper arm and shoulder even 6 days after the immunization.
Severe abdominal pain, nausea, loss of focus, syncope up to 5 times per day w seizure like activity, skin rashes, irritations, hives, chronic fatigue, Guillain Barre irregular menstrual cycle.  2 EDTA detox treatments, daily detox, advanced spinal care, 100% raw, organic low glycemic diet
neck pain; shoulder pain; whole arm is numb/fingers numb; arm pain; arm very weak; fingers are tingly; Nausea; Sharp back pain/middle back pain; Difficulty walking; I Seemed to be drunk; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Sharp back pain/middle back pain), MOBILITY DECREASED (Difficulty walking), FEELING DRUNK (I Seemed to be drunk), NECK PAIN (neck pain) and ARTHRALGIA (shoulder pain) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product IBUPROFEN for an unknown indication.    The patient's past medical history included Brain tumour, Heart disorder, Fibromyalgia and Disability.   On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started IBUPROFEN (unknown route) at an unspecified dose. On 17-Mar-2021, the patient experienced BACK PAIN (Sharp back pain/middle back pain), MOBILITY DECREASED (Difficulty walking), FEELING DRUNK (I Seemed to be drunk) and NAUSEA (Nausea). On 25-Mar-2021, the patient experienced NECK PAIN (neck pain), ARTHRALGIA (shoulder pain), HYPOAESTHESIA (whole arm is numb/fingers numb), MYALGIA (arm pain), MUSCULAR WEAKNESS (arm very weak) and PARAESTHESIA (fingers are tingly). The patient was treated with NAPROXEN AMINOBUTANOL at an unspecified dose and frequency and FOSFOMYCIN TROMETAMOL (FOSIROL) at an unspecified dose and frequency. At the time of the report, BACK PAIN (Sharp back pain/middle back pain), MOBILITY DECREASED (Difficulty walking), FEELING DRUNK (I Seemed to be drunk), NECK PAIN (neck pain), ARTHRALGIA (shoulder pain), NAUSEA (Nausea), HYPOAESTHESIA (whole arm is numb/fingers numb), MYALGIA (arm pain), MUSCULAR WEAKNESS (arm very weak) and PARAESTHESIA (fingers are tingly) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       treatment includes Ibuprofen, Naproxen and Fexeril. concomitant product is not provided   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: New adverse event is mentioned (middle back pain, arm pain, neck pain,shoulder pain and whole arm is numb)
Information has been received from a consumer concerning her 20 year old daughter with no medical history, no known allergies who in December 2007, was vaccinated with a third dose of GARDASIL (Lot # not reported). There was no concomitant medication. In May 2008, the patient experienced severe headaches, dizziness and muscle pain after receiving three doses of GARDASIL (dates of first and second dose were not reported). The patient's mother reported that the patient is in so much pain she is unable to lift her head off her pillow. An MRI and CAT scan were reported as normal. At the time of reporting the patient had not recovered. The patient sought medical attention at the office. There was no product quality complaint. Additional information has been requested.
then sx HA fever congestion moderate 06Jun PM; fever; This is a spontaneous report received from a non-contactable reporter(s) (Nurse).  A 31-year-old male patient received BNT162b2 (BNT162B2), on 21Dec2021 as dose 3 (booster), single (Lot number: FF2589) at the age of 31 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine ([{prev_dose_product=COVID 19,, prev_dose_brand_unknown=True,, prev_dose_brand_name_unknown=C, COVID19 Vaccine,, prev_dose_lot_unknown=True,, prev_dose_lot_unknown_reason=Not, available/provided to reporter at the, time of report completion,, prev_dose_dose_number=2},), for covid-19 immunization; Covid-19 vaccine ([{prev_dose_product=COVID 19,, prev_dose_brand_unknown=True,, prev_dose_brand_name_unknown=C, OVID19 Vaccine,, prev_dose_lot_unknown=True,, prev_dose_lot_unknown_reason=Not, available/provided to reporter at the, time of report completion,, prev_dose_dose_number=1},), for covid-19 immunization. The following information was reported: PYREXIA (non-serious) with onset 06Jun2022, outcome "unknown", described as "fever"; NASAL CONGESTION (non-serious) with onset 06Jun2022, outcome "unknown", described as "then sx HA fever congestion moderate 06Jun PM". Relevant laboratory tests and procedures are available in the appropriate section. It was unknown if therapeutic measures were taken as a result of nasal congestion, pyrexia.  Additional information: Unknown If other vaccine in four weeks. Unknown if covid prior vaccination. Yes covid tested post vaccination  No follow-up attempts are possible. No further information is expected.
feels like my skin is tearing; Skin tear; nerve endings seem to be increasing in hyper activity; This case was reported by a consumer and described the occurrence of nerve damage in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In October 2019, the patient received the 2nd dose of Shingrix. In October 2019, immediately after receiving Shingrix, the patient experienced nerve damage. On an unknown date, the patient experienced skin pain and skin tear. On an unknown date, the outcome of the nerve damage, skin pain and skin tear were not recovered/not resolved.   It was unknown if the reporter considered the nerve damage, skin pain and skin tear to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The patient received Shingrix and had nerve endings seem to be increasing in hyper activity. It seems to be getting worse. In fact, as of the last 30 to 60days it feels like my skin was tearing or shirts feel like sandpaper to my skin.
Pt experienced headache right after injection. Also experienced flu like symptoms the next day. Hot; redness; arm swelling to elbow; hive like rash.
24 hrs after receiving ZOSTAVAX vaccine pt. started having pain at injection site, diarrhea, and profuse sweating. Pt. went to ER and was given Hydrocodone/APAP. On approximately 8/31/11 pt. states bruising occurred on Rt. upper arm and swelling on deltoid the size of golf balls.
Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Additional Details: Patient came into pharmacy with rash going down arm up to elbow. Received vaccine at another pharmacy last Tuesday (now Monday) and saw rash yesterday. Did not have rash until now. Counseled to take benadryl and let doctor know. If see no relief or have swelling of face/tongue even after taking benadryl to go to emergency ASAP.
This literature marketed report has been received from authors of a published article, referring to a 65-69 years old (age group also reported as adult) male patient with hepatitis C virus coinfection. The patient's medical history and concomitant medications were not reported. The patient had been received a long-term conservatorship or short-term acute-care psychiatric treatment in the hospital. The patient did not have a record of previous hepatitis A virus (HAV) immunity. On an unknown date in 2017, the patient was vaccinated with a single dose of hepatitis a vaccine, inactivated (manufacturer unknown) (route, lot # and expiration date unknown) for prophylaxis. In 2017 (reported as onset at day 26 from July 2107), the patient had clinical signs and symptoms (vomiting, lethargic, abdominal pain, jaundice) and laboratory results consistent with acute HAV infection. The laboratory results included alanine aminotransferase (ALT): 2419 U/L (highest measure within 1 week of illness); aspartate aminotransferase (AST): 1176 U/L (highest measure within 1 week of illness); bilirubin: 10.1 mg/dL; and the ribonucleic acid (RNA) genotype was 1B. The patient was hospitalized for 2 days for the event. The patient had close contact, shared living quarters and shared a hospital unit restroom with another patient who had immunoglobulin M (IgM) antibodies to HAV. The outcome of the event was unknown. The reporter considered the event to be related to hepatitis a vaccine, inactivated (manufacturer unknown).
Site of injection reddish; Injection site itchy; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Site of injection reddish) and VACCINATION SITE PRURITUS (Injection site itchy) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Site of injection reddish) and VACCINATION SITE PRURITUS (Injection site itchy). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE ERYTHEMA (Site of injection reddish) and VACCINATION SITE PRURITUS (Injection site itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication reported.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 25-Jan-2021: Per MR, the LLT and listing of the events were changed on 22-JUN-2021.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Total swelling, redness, heat  circumferentially around (right arm and part of forearm.  Symptoms of local itching.
Numbness in hands; tingling in hands; brother-in-law has the same thigh muscle weakness; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Numbness in hands), PARAESTHESIA (tingling in hands) and MUSCULAR WEAKNESS (brother-in-law has the same thigh muscle weakness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (Numbness in hands), PARAESTHESIA (tingling in hands) and MUSCULAR WEAKNESS (brother-in-law has the same thigh muscle weakness). At the time of the report, HYPOAESTHESIA (Numbness in hands), PARAESTHESIA (tingling in hands) and MUSCULAR WEAKNESS (brother-in-law has the same thigh muscle weakness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment details were reported.
Patient felt sweaty, dizzy and anxious. RN noted patient felt clammy and diaphoretic. VS obtained at 14:53- 110/72, 83, 22, and 97% SpO2 on room air. Patient offered and accepted water to drink, father at side. RN spoke calmly with patient and anxiety decreased. In less than 10 min, patient had no dizziness, anxiety, or any additional symptoms. Patient stated she was feeling much better. RN instructed patient's father to follow-up with PCP or report to ER if symptoms returned or worsened. Father verbalized agreement.
Information has been received from a nurse practitioner (also reported as a physician assistant) concerning "an approximately 24 year old" female with a history of seizures, who, on an unspecified date, was vaccinated IM with a first dose of Gardasil.  It was reported by the nurse practitioner that the patient had never been diagnosed with anything.  Within thirty minutes post vaccination the patient experienced a seizure.  The patient was sent to the emergency room.  At the time of the report, the outcome of the patient was unknown.  No product quality complaint was involved.  Upon internal review seizure was considered to be an other important medical event.  Additional information has been requested.
After receiving the Rotavirus vaccine was extremely pale and lethargic. Will not be receiving anymore Rotavirus vaccine.
This case was reported by a consumer and described the occurrence of vasculitis legs in a 65-year-old female patient who received FLULAVAL QUADRIVALENT 2015-2016 season (batch number 7754S, expiry date 1st June 2016) for prophylaxis. Co-suspect products included FLULAVAL QUADRIVALENT 2016-2017 season (batch number A3AD2, expiry date 1st May 2017) for prophylaxis. On 16th October 2015, the patient received the 2nd dose of FLULAVAL QUADRIVALENT 2015-2016 season (intramuscular) .5 ml. On 15th September 2016, the patient received the 3rd dose of FLULAVAL QUADRIVALENT 2016-2017 season (intramuscular) .5 ml. In October 2015, 6 days after receiving FLULAVAL QUADRIVALENT 2015-2016 season and FLULAVAL QUADRIVALENT 2016-2017 season and not applicable after receiving FLULAVAL QUADRIVALENT 2016-2017 season, the patient experienced vasculitis, rash, skin discoloration and joint pain. In September 2016, the patient experienced vasculitis, rash, skin discoloration and joint pain. On an unknown date, the outcome of the vasculitis, rash, skin discoloration, joint pain, vasculitis, rash, skin discoloration and joint pain were unknown. It was unknown if the reporter considered the vasculitis, rash, skin discoloration and joint pain to be related to FLULAVAL QUADRIVALENT 2015-2016 season. It was unknown if the reporter considered the vasculitis, rash, skin discoloration and joint pain to be related to FLULAVAL QUADRIVALENT 2016-2017 season. Additional details were provided as follows: The age at vaccination was not reported. On 16th October 2015 01:12, the patient received 2nd dose of FLULAVAL QUADRIVALENT 2015-2016 season and on 15th September 2016 10:12, the patient received 3rd dose of FLULAVAL QUADRIVALENT 2016-2017 season. In 2015, 2016, and 2017, the patient had the flu vaccine, 6 days after each dose, the patient experienced vasculitis. The patient experienced a severe rash on legs and trunk which lasted about a month, with some residual discoloration on legs and also experienced joint pain. Follow up information received from physician on 19th November 2018: The reporter's contact details were updated. The patient's demographic details were updated. On 10th September 2017, the patient received FLUZONE HIGH DOSE solution 0.5ml (intramuscularly), In September 2017, 6 days after vaccination the patient experienced lower extremity vasculitis. The patient has had 3 episodes of lower extremity vasculitis biopsy was done by dermatology showed IgA vasculitis. On an unknown date, the outcome of the vasculitis, rash, skin discoloration, joint pain, vasculitis, rash, skin discoloration and joint pain were unknown. It was unknown if the reporter considered the vasculitis, rash, skin discoloration and joint pain to be related to FLUZONE HIGH DOSE solution. The VAERS details were updated. The patient gave authorization to contact their physician. Lab Comments: On an unknown date, biopsy done by dermatology showed as IgA vasculitis. Sender's Comments: US2018GSK007391: Previous VAERS submission in paper format.
Within 3 days of the vaccine, I was off balance/dizzy, fatigued, brain fog, short term memory issues, nausea and no appetite, left inner ear swollen with fluid, tinnitus/ear ringing constantly. These issues lasted 4 weeks. Tinnitus and a little imbalance still happening.
Vaccine was administered on 05/24/2021 at 11:30 AM.  Patient began feeling Dizziness at 11:41 AM  Notified Dr.  Obtain vitals: at 11:41 AM Spo2: 98% Pulse : 89 BP: 100/64 mmHg. Per provider,  provided Gatorade for hydration, and monitored patient for another 30 minutes. After 30 minutes symptoms were relieved Vitals taken upon releasing patient  at 12:15 PM BP: 100/70mmHg  Spo2: 97%    Pulse: 82-91. and patient was released home
Pt developed morbilliform rash on face -> trunk -> extremities, onset about 12 hour after vaccines. Evolved to erythema multiforme rash without mucosal involvement. 2 ER visits (5/29 & 5/30), Rx with Diphenhydramine & Ranitidine.
Fever of 102-103 started 24 hours after vaccine. Also had dizziness, headache & sore throat, that was relieved by ADVIL but kept coming back. She went to the doctor on 10-21-08 - 4 days post vaccine when symptoms persisted. She was also not responding with reduction of fever after ADVIL on 10-21-08.
As an intern was administering the vaccine (into the left arm) the needle separated from the syringe, therefore a large portion of the vaccine did not make it into the patient's arm. Per CDC recommendations (Appendix A), a full dose was administered into the right arm (opposite of the error). Patient did not suffer any acute reactions but will follow up in the event a serious reaction occurs.
Caller reports that normally she can't see at night when she drives but since she got the second shot she can see clearly at night better without her glasses; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Caller reports that normally she can't see at night when she drives but since she got the second shot she can see clearly at night better without her glasses) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 0R8E211A and 088D211A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (Patient mentioned having a positive Covid19 diagnosis 24November2020-14Janurary2021.) from 24-Nov-2020 to 14-Jan-2021.   On 03-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Caller reports that normally she can't see at night when she drives but since she got the second shot she can see clearly at night better without her glasses). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Caller reports that normally she can't see at night when she drives but since she got the second shot she can see clearly at night better without her glasses) outcome was unknown.            Concomitant medications include blood pressure medication. Treatment medications include Tylenol extra strength and used a heating pad for her arm. Caller reports that normally she can't see at night when she drives but since she got the second shot she can see clearly at night, better without her glasses beginning at the end of August/beginning of September.   This case was linked to MOD-2021-350653 (Patient Link).
Headache, body ache, nausea, diarrhea, cold sweats, fever Still experiencing these
Narrative:  Patient decided to not get second shot because stated after he got home was feeling short of breath from the first. allergy was added to profile.
Pt states became dizzy and nauseous after flu shot - states her face was hot and "weird".
This spontaneous report was received from a healthcare worker refers to an unspecified number of patients of unknown age and gender. Pertinent medical history, drug reactions/allergies and concomitant medications were not reported. On an unknown dates, the patients were vaccinated with improperly stored GARDASIL, lot # L000610, expiry date 31-JAN-2017, (dose, frequency and route of administration not reported). No adverse symptoms reported. No product quality complaint (PQC) was involved. No further information provided. This is one of three reports received from the same reporter. Additional information has been requested.
I already have some muscle pain; This is a spontaneous report from a contactable consumer (patient). A 77-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: EL0142, expiry date not reported), via an unspecified route of administration on 07Jan2021 09:30 at single dose on right arm for COVID-19 immunization. Medical history included none. There were no concomitant medications. The patient reported that she received the first dose of the vaccine yesterday (Thursday, 07Jan2021) and is scheduled to have the 2nd dose on 28Jan2021. She is asking if she should delay her Aerobics class the next day after the 28th because she knows that there are flu like symptoms that are associated with the 2nd dose of the vaccine. The patient stated, "What are the side effects after the 2nd dose? I already have some muscle pain." The patient also denied having any problems or symptoms after yesterday's shot (as reported, pending clarification). No other vaccine received that day and none in the 4 weeks prior. Not had any problems with the vaccines in past. When looking for name of vaccine states it was the one from Pfizer that was frozen, 170 degrees below zero. Mentions she is not a flu vaccine person and did not know if that matters. The adverse event did not require a visit to the Emergency Room or Physician Office. No relevant tests done. The outcome of the event was unknown.
patient stated felt numbness in her left middle finger and thumb. Started feeling lightheaded and though she was going to pass out. Patient states she has needle phobia and has had this happen in the past.